Blog

Archive: June 2025

Biomarkers and imaging in Alzheimer’s disease: Understanding Amyloid and Tau within the ATN Framework

Beta-Amyloid and tau accumulation in Alzheimer’s disease Drug development for Alzheimer’s disease (AD) continues to face significant challenges, largely due to the limited availability of reliable biomarkers and the high risk of trial failure.

A Quick Guide to Imaging Analysis & Operations Essentials in Alzheimer’s Disease Clinical Research

Why is harmonisation of imaging protocols important in Alzheimer's disease clinical trials? Harmonisation of imaging protocols is crucial in Alzheimer's disease clinical trials for several reasons. Firstly, it ensures consistency and accuracy across different trial sites, which is essential for reliable data collection and analysis.